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Abstract: Urinary incontinence (UI) is a major problem in health care and more than 400 million
people worldwide suffer from involuntary loss of urine. With an increase in the aging population,
UI is likely to become even more prominent over the next decades and the economic burden is
substantial. Among the different subtypes of UI, stress urinary incontinence (SUI) is the most
prevalent and focus of this review. The main underlying causes for SUI are pregnancy and childbirth,
accidents with direct trauma to the pelvis or medical treatments that affect the pelvic floor, such as
surgery or irradiation. Conservative approaches for the treatment of SUI are pelvic physiotherapy,
behavioral and lifestyle changes, and the use of pessaries. Current surgical treatment options include
slings, colposuspensions, bulking agents and artificial urinary sphincters. These treatments have
limitations with effectiveness and bear the risk of long-term side effects. Furthermore, surgical
options do not treat the underlying pathophysiological causes of SUI. Thus, there is an urgent need
for alternative treatments, which are effective, minimally invasive and have only a limited risk for
adverse effects. Regenerative medicine is an emerging field, focusing on the repair, replacement
or regeneration of human tissues and organs using precursor cells and their components. This
article critically reviews recent advances in the therapeutic strategies for the management of SUI and
outlines future possibilities and challenges.
Keywords: stress urinary incontinence; treatment; regenerative medicine; muscle stem cells
1. Introduction
The involuntary loss of urine remains a major medical issue with approximately 20%
of people affected at some point during their lifetime [1,2] and a three-to-one ratio between
women and men [3,4]. Patients suffering from urinary incontinence (UI) experience a
severely reduced quality of life (QoL) [5,6] and there is an unmet medical need including
continuously rising healthcare costs [7–10]. Among different types of UI, this article focuses
on stress urinary incontinence (SUI), the most prevalent subtype [1,11]. The International
Continence Society (ICS) defines SUI as “complaint of involuntary loss of urine on effort
or physical exertion including sporting activities, or on sneezing or coughing” [12]. The
etiology of this symptom is manifold but often caused by previous injury to the pelvic
floor. Damage can occur during childbirth or surgical treatments, radiotherapy of tumors,
as consequence of trauma to the pelvic floor or as an effect of aging [11,13]. Contributing
risk factors include obesity, smoking, the number of pregnancies and vaginal deliveries,
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menopause, polypharmacy and the presence of lung diseases causing chronic cough [14].
Current treatment options enable the recovery of continence with various outcomes [15].
However, until today, a definite solution for the correction of the underlying etiology is
lacking. Furthermore, the actual treatments only offer short-term relief, and the overall
success of these therapies is mostly limited due to complications and their sequelae [16].
The search for new solutions and different treatments has been ongoing for decades, but
without any great success. However, tissue engineering (TE) utilizing stem cells has
emerged as a promising regenerative and minimal-invasive solution for this multifaceted
disease [17].
2. Stress Urinary Incontinence
SUI is a major medical issue. Approximately 50% of the female population over 45 years
is affected and around 20% of men after 70 years of age [3,7,18]. There are several triggers
for urine leakage in SUI including coughing, laughing, sneezing, exercising and other
movements that increase the intra-abdominal pressure on the bladder that provoke loss of
urine in patients. Importantly for this type of UI, the leakage happens in the absence of
detrusor contraction.
The QoL in patients with SUI can be severely reduced due to limited daily activities
and the exposure to unpleasant sensation and odor caused by wet diapers, which often
leads to recurrent urinary tract infections [19]. SUI further affects sexuality and the personal
well-being, which provokes shame, depression, impaired productivity at work, reduced
employment and a higher possibility to be admitted to a nursing home at higher age [6,11].
The worldwide healthcare expenditures for the treatment of this condition are con-
stantly increasing. In the USA, it is estimated that the direct cost of caring for patients with
UI adds up to around $20 billion dollars per year [9,20,21].
2.1. Pathophysiology
Continence and micturition are achieved by a complex interplay of anatomical struc-
tures such as the urethral sphincter, detrusor, bladder neck, urethral smooth muscle,
nerves, vascular plexus and the surrounding tissue support [22]. There is an active and
passive component contributing to intraurethral pressure. This pressure is mainly gen-
erated by the rhabdosphincter (external urethral sphincter, striated muscles, intentional)
and the lissosphincter (internal urethral sphincter or “Hessian loop”, smooth muscles,
unintentional)–both belonging to the active component [23,24]. Normally, the urethral
pressure exceeds bladder pressure, resulting in continence. The proximal urethra and
bladder are both within the pelvis and an increased intra-abdominal pressure is transmit-
ted to both urethra and bladder equally. In case of an intact pelvic floor, this leaves the
pressure differential unchanged and therefore results in urine remaining within the bladder
(passive component). Normal voiding is initiated by the parasympathetic nervous system
through the pelvic nerve. As a result, urethral pressure falls (relaxation of sphincter) and
bladder pressure rises (detrusor contraction) [22]. During the filling phase, sympathetic
nervous activity inhibits the detrusor and activates the smooth urethral muscles (unin-
tentional), increasing the outlet resistance through hypogastric nerves and stimulation of
alpha-adrenoreceptors [24]. In addition, efferent pudendal nerve activity increases the
tonicity of the striated urethral sphincter (intentional). The sphincter complex prevents
UI by providing both resting urethral tone via slow-twitch fibers and rapid reflexive con-
traction, if the abdominal pressure rises quickly. However, the external urethral sphincter
(EUS) is, for the most part, responsible for preventing involuntary urine leakage. Therefore,
any damage to the EUS, pelvic floor, nerves or surrounding tissue may lead to SUI.
A further important term is intrinsic sphincter deficiency (ISD), which tries to subsume
muscular sphincter dysfunction. However, experts often disagree on the meaning and
implications of ISD. Clinically, it is mostly defined as a combination of severe SUI due to
low maximal urethral closure pressure (MUCP) and a low Valsalva leak point pressure
(VLPP) [25–27]. ISD can occur with or without the presence of a hypermobile urethra [15].
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Irrespective of pathophysiology, SUI is the result of high intra-abdominal pressure that
exceeds the urethral and pelvic floor pressure in the setting of a sudden increase of intra-
abdominal forces [28,29].
2.2. Etiology and Diagnostics
The etiology of SUI differs between men and women. In women, the cause of poor
urethral sphincter function is neither fully known, nor entirely understood. Nevertheless,
several important risk factors have been identified such as body mass index (BMI) and
advancing age. With increasing age, the loss of muscle fibers—turning into scar tissue—
goes along with the denervation of relevant structures of the pelvic floor. The number of
pregnancies with subsequent vaginal deliveries relevantly influences this development.
Therefore, nulliparous women or those having delivered by Cesarean section experience a
much lower risk for SUI. Further, hormonal changes during menopause, smoking, chronic
obstipation, cognitive impairment, irradiation or post-surgical complications all potentially
contribute to the development of SUI [14]. In addition, anatomical alteration, such as a
hypermobile urethra or pelvic organ prolapse, can also predispose for SUI. Interestingly,
symptoms usually worsen before menstruation. These facts imply that the estrogen and
progesterone level may have a relevant impact on urethral and sphincter function. As
pathophysiological explanation, lowered estrogen levels lead to reduced muscular pressure
around the urethra and therefore increasing the chances of involuntary leakage [30,31].
In men, the main causes for SUI are the adverse effects of radical prostatectomy. Despite
improved surgical techniques, persistent SUI rates have shown to vary between 10 and
30% [32].
According to the classification of Stamey, there are three grades of clinical SUI: Urine
leakage while coughing, sneezing or laughing (grade 1), while walking, climbing the
stairs or standing up (grade 2) or while lying horizontally (grade 3) [33]. The severity
of SUI can be easily quantified with bladder diaries, pad-tests and questionnaires. In
complex cases with suspicion of mixed UI or in order to clearly differentiate between the
subtypes of UI, a urodynamic investigation should be performed [34]. With urodynamics,
the urologist wants to rule out potential concomitant diseases from the urinary tract, which
would hamper the operative result [35]. Before planning a specific therapy, a sonographic
examination of the whole urinary tract (including uroflowmetry with post void residual
volume testing) and the exclusion of a lower urinary tract infection is needed [36].
2.3. Treatment
Various treatment options are available for patients suffering from SUI. Most im-
portantly, the choice of a specific therapeutic pathway depends on the clinical severity
and objective psychological burden and must be well discussed and selected together
with the particular patient adapted to her/his individual needs. Importantly, a stepwise
approach with initial conservative and later minimal invasive to invasive treatment is
strongly recommended to minimize the risk of therapy-associated morbidity [37–39].
Current treatment options can be divided into three different categories: conservative,
pharmacological and surgical [37,38]. The conservative options include pad usage, catheters
or urinals, weight loss, smoking cessation, reducing unnecessary medication, behavioral
therapy (i.e., bladder training, fluid/dietary modification, reducing caffeine intake) and
physiotherapy as well as electrophysiological stimulation of the pelvic floor [11,19]. The
key problems of pelvic-floor muscle training are lack of motivation, missing continuity
and inconsistency in execution, all negatively affecting the training benefits of patients.
An alternative to conservative treatment forms are the usage of vaginal pessaries or the
insertion of urethral plugs.
From the Food and Drug Administration (FDA), there are no approved pharmaco-
logical treatments for SUI. Anticholinergic agents and/or beta-3 receptor agonists are
most often used for clinical pictures of mixed urinary incontinence (SUI combined with
overactive bladder). Additionally, the use of selective serotonin noradrenaline inhibitors
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(SSNRI), estrogens and desmopressin may be supportive. The available surgical options
are manifold: paraurethral injection therapy (“bulking agents”), tension free vaginal tapes
(TVTs), pubovaginal or mid-urethral urethral slings (retropubic vs. transobturatorial vs.
autologous fascia), Burch colposuspension (open or laparoscopic) and artificial urinary
sphincter and compression systems [11,40–43]. These interventions render a significant
amelioration of the clinical symptoms and enable the recovery of continence with around
80% cure rates [44]. However, these options offer short-term relief only and they tend to
cause complications in the short- and long-term perspective such as bladder or vaginal per-
foration, voiding or storage dysfunction (urinary retention or new onset urge UI), chronic
pelvic pain, urethral and vaginal erosions or material infections [45]. In addition, around
10% of patients undergoing surgery for SUI will have worsening symptomatology due to
new onset of detrusor overactivity (DOA) causing urgency incontinence [45,46]. This may
lead to further operations or the need for explanation of the foreign materials.
3. The Regenerative Approach
To date, a definitive correction of the underlying etiology of SUI has not been accom-
plished. Therefore, the search for alternative solutions and regenerative treatment options
are of paramount importance. TE is a field of regenerative medicine and includes the
principles of cell transplantation, material science and bioengineering for the development
of biological substitutes that may be used as autologous transplants to restore or main-
tain organ function. Precursor cells are isolated from living human tissue biopsies and
thereafter multiplied in vitro. Later, these explanted cells are mixed with or seeded onto
biodegradable polymers, and are replanted to repair or replace the injured or diseased
tissue. The overall goal is the integration of the bioengineered cells into the surrounding
tissue to rebuild a functional organ. Cell-based therapies are proposed as a method to
achieve restoration of numerous tissues and organs. A huge advantage of autologous
TE approaches over conventional organ transplantation is the fact that immunosuppres-
sion can be omitted, because the patient’s own cells are not rejected by the recipient’s
immune system. Furthermore, patients are not dependent on the limited availability of
transplantable organs. However, this approach is technically demanding, expensive and
needs a broad combination of knowledge from different basic and clinical research fields.
A particular option is the implantation of autologous muscle stem cells into the
sphincter area to strengthen and restore EUS function [47]. Figure 1. The implanted stem
cells would then increase MUCP to resist higher intra-abdominal strain [17]. Nevertheless,
the process of cell isolation, expansion, harvesting and implantation is a complex, expensive
and a critical endeavor, which is dependent on the effects of culture on cell biology at the
molecular level.
Embryonal, umbilical cord and adult stem cells are most commonly used for such
a treatment. Due to immunological, oncological and ethical considerations, research has
focused on the latter for quite some time. Adult stem cells are mainly isolated from either
adipose tissue, bone marrow or skeletal muscle [48]. Recent advances in cell-based ther-
apies have provided a variety of opportunities to seek alternative solutions in restoring
damaged sphincter function in patients with UI [49]. Functional restoration of the dam-
aged EUS using the patient’s own cells would be an ideal treatment option that could
reverse the underlying pathologic condition. The application of such treatments belongs
to the category of advanced therapy medicinal products (ATMP), which underlie strict
control mechanisms and various regulations from ethical, pharmacological and medical
supervisory authorities. The stringent supervision serves as quality control and assures
the transfer of relevant information within the involved study teams and between good
clinical (GCP) and manufacturing practice (GMP). This is critical for translating a promising
achievement from the laboratory bench to the patient’s bedside, and later into a specific
treatment of clinical daily routine [50]. Many studies have explored the preclinical and
clinical application of stem cells isolated from various origins that have promising results
for the treatment of SUI [51–65] and were summoned up as part of the several reviews
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articles. Hart and colleagues summarized the mainly preclinical published literature on
cell therapy models for the regeneration of smooth and striated urethral sphincter muscles,
but also the regeneration of nerves and neuromuscular synapses [47]. Earlier, Lin et al.
analyzed the literature in a review on different cell injection routes (transurethral, peri-
urethral and intravenous), cell labeling, functional and histological assessment from mainly
animal models of preclinical trials [66]. In 2016, Williams et al., mainly focusing on animal
models, summarized the current state of knowledge on cell therapy for SUI introducing
regenerative pharmacology as an adjunct or replacement [67]. A Chinese and American
collaboration wrote a review with new aspects on the preclinical usage of tissue-engineered
suburethral slings, that combine mechanical and regenerative aspects of stem cell therapy
in SUI [48]. They also pointed out nicely the six biggest challenges to success in stem cell
treatment. These are optimal dose and delivery route, proliferation and differentiation,
distribution, abnormal differentiation or neoplastic transformation, nerve regeneration
and adequate animal models to mirror chronic condition. Lastly, Vinarov and colleagues
published a thorough literature review, putting together all the available evidence on
preclinical and clinical studies using different stem cell types [68]. Nevertheless, the risk of
aberrant cell populations is always present, which may lead to non-functional scar tissue
(i.e., fibroblasts) or even tumor growth (i.e., teratoma). Hence, the main challenges are to
avoid deviations of precursor cell lines and to lead them into the right branch of differenti-
ation [50]. Further, the microenvironments of the tissue surroundings change significantly
and paracrine effects such as those exerted by chemokines, secretomes, cytokines, growth
and angiogenic factors become important determinants of cell fate [69].
3.1. Muscle Progenitor Cells (MPCs)
Regeneration of skeletal muscles is a highly orchestrated process that involves tight
regulation of multiple cellular and molecular responses. Satellite cells can be found in
the sublaminar layer of every skeletal muscle and are normally in a resting state. Upon
certain stimuli (i.e., trauma or strain), they re-enter the cell cycle and differentiate into
muscle progenitor cells (MPCs). The majority of MPCs are committed to the myogenic
lineage and are therefore most suitable for muscle engineering. Extensive studies have
examined this process in detail and have shown that MPCs are an ideal cellular model
to study muscle tissue regeneration in the preclinical and clinical setting (see following
paragraphs). Interestingly, MPC-based therapies have been proposed not only as a novel
treatment option for SUI, but also in various other muscle diseases (genetic and acquired
muscle disorders) [70,71].
3.1.1. Preclinical Data
The use of injectable cultured MPCs for the treatment of SUI was analyzed in various
animal studies, such as rodent, porcine, canine and primate models. Chancellor et al.
introduced the general strategy of using adult stem cells for the treatment of UI in the
early millennial years. These researchers injected muscle-derived stem cells (MDSCs) into
rats and were able to show that the cells persisted longer in situ than bovine collagen
as comparison [72,73]. Further, the injected MDSCs led to the formation of myotubes
and myofibers in the histological analysis. Even more important was that the cells were
not rejected, providing support that the injection of autologous cells was feasible and
safe in such a model. Another early study demonstrated that MPCs harvested from limb
skeletal muscles in mice may enhance the regeneration process of striated urinary sphincter
muscle after 1 month [74]. A further study reported that the periurethral injection of
allogenic MDSCs improved the leak point pressure (LPP) in sciatic nerve-transected female
rats compared to sham treatment [75]. Highly promising results in dogs indicated that
autologous MPCs were able to restore otherwise irreversibly damaged urinary sphincter
function with up to 80% of the initial closure pressure values in urodynamic analysis [28].
The injected cells were histomorphologically analyzed after 6 months and were able to
survive and form mature, functional tissue within the damaged region. The long-term
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effect on urinary sphincter deficiency after autologous MPC injection was also examined in
a nonhuman primate model with a previously transected pudendal innervation [76]. The
promising results showed sustained structural and functional restoration of the maximal
urethral pressure after 12 months. However, multiple factors (such as age, stress and body
weight) may negatively affect the efficacy of MPC treatment in chronic urinary sphincter
deficiency [77]. A recent study from Zhou and colleagues was able to demonstrate the
presence and location of tissue-resident progenitor cells in the EUS through label-retaining
cells at 1, 2, 3, 4 and 8 weeks after intraperitoneal injection of 5-ethynyl-2-deoxyuridine [78].
The thickness of the striated muscle layer in the EUS developed faster than the smooth
muscle layer after injection, whereas stem cells were located densely adherent to muscle
fibers directly under the basal membrane of laminin. Overall, these animal studies indicate
the feasibility of using autologous cells of muscle origin for functional restoration of urinary
sphincter muscle in animal models with sphincter deficiency.
 
Figure 1. Schematic visualisation of an intrasphincteric injection of muscle precursor cells (MPCs) to
regenerate the muscle tissue of the EUS. Adapted from © Jasmin Hegetschweiler and Nina Schwarz.
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3.1.2. Clinical Data
The translation of preclinical studies and their results to clinical application is highly
demanding. Unfortunately, the treatment of urinary incontinence with MDSCs has fallen
into disrepute in 2008 due to ethical concerns about research work, in which excellent short
time results were presented [79,80]. The researchers added up to 50% of pure fibroblasts
to the cell injections and used the same collagen concentration as chosen for conventional
bulking interventions, a strategy known to show acceptable short-term results only. Their
work was retracted due to irregularities in conduct of work, documentation of source data
and obtainment of patient consent. Nonetheless, the same group continued their research
with convincing results in female as well as male patients with SUI, followed-up until
1 year after the intervention [61,81,82].
Nevertheless, the general approach of using adult cells for the treatment of SUI was
further pursued by Sèbe et al., who reported results from 12 female patients who received
intrasphincteric injections of autologous MPCs isolated from a biopsy of deltoid muscle [83].
Ten out of 12 patients were either dry or improved on pad tests, while QoL improved in
half of the patients after 1 year of follow-up. In 2012 and 2013, Blaganje and Lukanovic
published two articles of ultrasound-guided myoblast injections into the EUS followed by
electrical stimulation (to enhance cell integration) as 2-step treatment in SUI of 38 female
patients [84,85]. At follow-up 6 months after the intervention, the results showed a well-
tolerated procedure, no reported adverse effects and that more than 75% of patients were
either cured or had an improved SUI. Gerullis et al. investigated the safety, efficacy and
effect of transurethral injection of autologous MDSCs in the damaged urethral sphincter of
222 male patients with postprostatectomy incontinence [86]. The therapy was effective in
only half of the patients, where the treatment led to either continence (12%) or improvement
(42%) of clinical symptoms. Chancellor and his group published a clinical trial in 2013,
where they injected 38 women with low or high doses of autologous MDSCs from biopsies
of the quadriceps muscle [87]. Patients were able to choose a second injection of the same
dose after 3 months and the follow-up ended 12 months after the last treatment. No
serious adverse events or major complications were reported and the majority of patients
experienced a 50% or greater reduction in pad weight (89% vs. 62%) and in reported stress
leaks (78% vs. 53%), favoring the group with the higher dose of injected cells. In 2014,
Chancellor et al. reported a study using pooled data from 80 female patients with different
doses of autologous MDSCs injected (range: 10–200 million cells) [88]. The higher dose
groups also tended to have a more favorable effect on continence, measured using pad
weight, stress leaks and questionnaires. Yiou et al. tried to avoid the complex and costly
process of stem cell isolation and expansion [89]. Therefore, the injected freshly isolated
myofibers from the gracilis muscle carrying MPCs in five males and five females with ISD.
Continence improved during the 12 months follow-up in four out of five women and their
MUCP increased twofold. In men, the effect on continence was moderate, while MUCP
recordings showed similar improvement. Gras et al. chose a similar approach with the
implantation of freshly harvested and minced skeletal muscle [90]. In a cohort of 35 women
with uncomplicated and complicated SUI, significant reductions in the mean number
of leakages and amelioration of patient reported outcomes (PROs) through scores from
questionnaires (ICIQ-SF = International Consultation on Incontinence Questionnaire–Short
Form) were witnessed. Stangel-Wojcikiewicz et al. presented data on functional results with
complete or partial improvement in 75% and a significantly improved QoL after two and
four years of follow-up in 16 female patients treated for SUI with MPCs [91,92]. The longest
follow-up of 36 months after treatment with injections of autologous MDSCs was presented
by Sharifiaghdas et al. [93]. Seven out of 10 female patients with SUI due to trauma were
either cured or experienced improved results on MUCP measured by urodynamics or in
cough stress and 1 h pad tests. In 2018, Jankowski and colleagues performed a double-blind,
randomized and placebo-controlled trial evaluating the safety and efficacy of autologous
MDSCs and placebo in 50 female patients with SUI and 93 controls [94]. The enrollment of
patients was halted at 60% of planned subjects due to an unexpectedly high placebo rate
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(90%). They concluded that primary efficacy endpoints need to be clinically meaningful
and selection criteria well defined to lower placebo response rate and to reveal a possible
treatment effect. A summary of the clinical data is presented as Supplementary Table S1.
3.2. Routes of Application
The route and precision of an injection therapy in SUI is of veritable importance
to achieve an accurate effect of a regenerative or other minimal-invasive therapy form.
Therefore, not only for the regenerative approach using MPCs, but also for bulking agents
a precise injection into EUS is an indispensable premise. Several approaches using needle
injection were described in the literature: (a) transurethral by either endoscopic or ultra-
sonographic guidance, (b) periurethral and (c) transperineal. Just recently, the feasibility
and accuracy of a new transurethral injection technique for the purpose of MPC implan-
tation was published [95]. Only a few studies have compared the outcomes of different
injection routes among each other [96–98]. Studies including urethral injection therapies
for the treatment of female SUI were analyzed in a recent Cochrane review, demonstrating
no evidence for a clear superiority regarding a particular application form [99]. A novel
technique described by Jaeger et al. used a needle-free method with waterjet technology to
deliver mesenchymal stromal cells (MSCs) into the EUS [56]. The homogenous distribution
of stem cells within the urinary sphincter through a “spray effect” may advance to the
predominant method of injection in the future. A recently published manuscript by the
same group has demonstrated superiority of the waterjet technology over endoscopic nee-
dle injections regarding on-site precision [100]. Additionally, the implantation of porcine
adipose tissue-derived stromal cells (pADSCs) was faster and more homogenous with
waterjet technology and showed morphologically intact and viable cells after histology of
cryosections of the EUS.
3.3. Neuromuscular Electromagnetic Stimulation (NMES)
Implanted MPCs can be treated with external neuromuscular electromagnetic stim-
ulation (NMES) to enhance cell proliferation and the differentiation into the myogenic
lineage to ameliorate functionality through optimal embedding into the surrounding tissue.
NMES has the ability to induce muscle contraction and has been proposed as a therapeutic
modality for skeletal muscle diseases [101]. Magnetic stimulation also supports nerve and
muscle regeneration by activating muscle-nerve cross-talk and inducing the maturation
of neuro-muscular junctions in mice [102]. Further, NMES improves muscle regeneration
by minimizing the presence of inflammatory infiltrate and the formation of scars after
trauma [102]. It inhibits posttraumatic atrophy, induces hypertrophy and increases the
metabolism and turnover of the muscle.
A therapeutic chair, inducing pulsed magnetic stimulation for the exercise of pelvic
floor muscles in 120 females with SUI, has been shown to significantly improve ICIQ-scores
in up to 75% of participants after 16-32 sessions and one year of follow-up [103]. A Japanese
research team investigated the effect of magnetic stimulation on SUI in female patients
being refractory to pelvic floor physiotherapy [104]. Patients were randomized 2:1 to either
NMES or sham treatment: 30 individuals completed the trial with 24h pad tests, ICIQ-
scores and QoL questionnaires that were significantly better compared to before NMES
treatment as well as compared to the sham treatment group. An observational study from
Vadala et al. reproduced similar findings in 10 female and 10 male patients suffering from
SUI [105], where MUCP and urethral functional length increased significantly compared to
baseline values.
3.4. Imaging Technologies for MPC Tracking
The fate of MPCs after implantation demands to be further investigated with non-
or minimal-invasive methods. Therefore, novel imaging technologies are needed. The
possibility of using positron emission tomography (PET) in CT imaging to non-invasively
monitor implanted MPCs, that have been genetically modified to express dopamine 2 recep-
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tors (D2R), has been investigated [106]. 18F-Fallypride PET radioligands were successfully
used to visualize the MPCs by fluorescent microscopy and confirmed sustained survival of
the transplanted cells at different time-points with formulation of muscle tissue at the site
of injection. Another approach utilized superparamagnetic iron oxide (SPIO) nanoparticles
for the tracking of MPCs using magnetic resonance imaging and X-ray micro-computed
tomography (µCT) in rat hearts [107]. Histological and imaging analysis revealed that
iron-oxide particles were confined to viable, skeletal muscle-derived cells in the implant at
the expected location based on magnetic resonance imaging (MRI) and µCT. No evidence
of phagocytosis of labelled cells by macrophages was documented after 1 year. Others
have used unified fusion reporter genes, whose expression can be monitored with biolumi-
nescence imaging, for the localization of viable MPCs following implantation into a mouse
model [108]. An advantage of this approach is the possibility to merge multiple imaging
modalities. Recently published research presented the use of polymer-entrapped perflu-
orocarbons to label human cells, which can be visualized with photoacoustic imaging,
Fluorine-19 (19F) MRI, US or fluorescence [109]. These nanoparticles enable the mea-
surement of pharmacokinetics and biodistribution or the tracking of injected precursor
cells [110–112]. However, all these techniques require the preparation of stem cells with
radioligands, SPIOs, nanoparticles or antibodies for bioluminescence imaging and may
even need imaging modalities using emission of radiation. A promising, non-invasive
and non-radiogenic imaging method for the evaluation and the functional assessment of
(pelvic) muscle structures are MR diffusion tensor imaging (DTI) [113–117] or magnetiza-
tion transfer (MT) for the analysis of muscle tissue formation [118,119]. DTI and MT are
able to provide a quantitative and qualitative measurement of the muscular microstructure
and its physiological processes as well as of the fiber formation after in vivo myogenic
differentiation of human MPCs [120,121].
3.5. Chemokine Therapy
Regenerative Pharmacology is a field of Regenerative Medicine that seeks to use small
molecules (or combination of molecules) to stimulate the body to self-heal in situ [122].
It is distinct from standard pharmacotherapy, which is often limited to the amelioration
of symptoms. This approach has the potential of bypassing the lengthy, expensive and
complicated cell isolation and implant pre-conditioning protocols of conventional regener-
ative medicine. It is also one of the few remaining unexplored approaches for regenerating
the lower urinary tract. Current efforts are underway to identify the cell secretions and
determine their individual or combined regenerative efficacy. Lavoie et al. and Deng et al.
found that the sum of secretions from progenitor cells stimulate structural and functional
regeneration of the urethra [123,124]. Williams et al. have published that local sphinc-
ter administration of CXCL12 (also known as stromal cell-derived factor 1), without cell
therapy, restores short-term urinary sphincter structure in NHPs with chronic sphincter
deficiency [125]. An effect related to the ability of CXCL12, but not cells, to mobilize bone
marrow cells and restore vascularization and innervation [125]. A cautionary note for this
approach is that molecules do not function in a vacuum and interact with other molecules.
As such, a thorough knowledge of their mechanisms of action are required. For instance,
studies using recombinant CXCL12 injections have shown positive effects on tissue regener-
ation [125,126]. However, there are published studies that seem to contradict these results
and dispute the beneficial effects of CXCL12 on urological tissues [127,128]. Nevertheless,
these studies focused on the secretion of physiologic CXCL12 that Ray et al. showed
to form dimers in physiologic conditions. High concentrations, which more efficiently
activate pathways may lead to pathology and malignancy and inhibit chemotaxis [129].
Veldkamp et al. also suggested low concentrations of monomeric CXCL12, which stimu-
lates and is the active form for chemotaxis [130,131]. Monomeric CXCL12 is secreted by
both mammalian cells and bacteria and is commercially available in recombinant, purified
form and used for current treatment injections. Thus, how the molecule is tested, the dose
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of the molecule and its interaction with other pathways are critical for the translation to
human use.
4. Discussion and Future Prospects
SUI is not a deadly disease compared to cancer or cardiovascular entities and there-
fore treatment never of imminent character. Nevertheless, it is with no doubt a chronic
condition that is associated with low QoL, many potential sequelae and high cumulative
healthcare costs. A solution for SUI with its ever-increasing patient numbers and a patho-
physiologically complex etiology is yet to be found. Despite the immense progress towards
a successful implementation of cell-mediated therapies to treat SUI, several key aspects
still need further investigation and improvement.
It will be necessary to enhance the survival and metabolism of the injected cells, in
order to improve the quality and functionality of the bioengineered tissues. The tracking of
long-term viability and function of implanted cells is critical–finding a tool to precisely and
non-invasively monitor cell fate would be a major breakthrough. Herewith, an accurate
implantation is an indispensable premise for MPCs to differentiate into striated EUS,
which is the fundament to a reasonable subjective and objective clinical outcome at a
later time point. Promising future techniques include direct visual control through an
endoscopic approach, additional to the ultrasound guidance. Further, the use of innovative
technologies such as waterjet injections demonstrated a homogeneous distribution of
stem cells in the periurethral target region of the EUS. Some published articles have
shown an impressive precision and excellent repeatability of such procedures in preclinical
animal studies [56,100]. This groundbreaking technique will most probably receive the
permission to be applied as future method of cell implantation in regenerative clinical trials
treating SUI.
Long-term results can be monitored with either urodynamic studies or non-invasive
and non-radiogenic imaging modalities. The advantage of functional MR imaging is
the combination of cell-tracking and the assessment of EUS function at the same time,
whereas urodynamic studies provide a functional evaluation only. An interesting future
alternative for non-invasive in vivo imaging of MPCs after injection would be tracking
with the help of nanoparticles (polymer-entrapped perfluorocarbons) in 19F MRI or US.
Apart from imaging, the direct effect of NMES remains unclear to date. This needs to
be further elucidated in prospective research trials, where muscle stem cells are used to
treat SUI, in order to analyze the treatment effect of NMES as in subjective and objective
functional results.
On the regenerative therapy side, there is potential for alternative strategies in the field
of regenerative pharmacology, which already showed promising early results and need to
be further developed. Chemokine treatment seeks to use small molecules (or a combination
of molecules) to stimulate the body to self-heal in situ [122]. Current efforts are underway
to identify the cell secretions and to determine their individual or combined regenerative
efficacy. Surely, the dose of the molecule and its interaction with other pathways are
critical for the translation to human use. To ameliorate the effect of chemokines, the use
of stable and biocompatible drug-delivery systems could be a promising modification.
Cubosomes are an example of lipid-based nanoparticles for the protected delivery of any
biomacromolecule to the target region in order to enhance the in vivo efficiency of the
carried drug [132]. Since therapeutics tend to be susceptible to degradation by enzymes,
cubosomes would improve bioavailability and cellular uptake of specific pharmacological
therapies in a correct dosage. However, upon cellular uptake the efficient release at its
target location is the first challenge to consider when designing nanocarriers. Another
possible strategy to ameliorate the regenerative treatment outcome in patients with SUI
could be the repeated injections of autologous MPCs in the same patient. If we manage to
establish freezing-thawing cycles without a relevant loss of cell count and viability, patients
will not need additional muscle biopsies and the dosage of the applied MPCs could be
adjusted. In combination with the stimulation of injected adult muscle stem cells through
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the application of NMES and/or ongoing pelvic floor physiotherapy, the ideal result would
be a long-lasting functional effect.
5. Conclusions
Despite the immense progress towards the successful implementation of cell-mediated
therapies to treat SUI, several key aspects still need further investigation and improvement.
It will be necessary to enhance the survival and metabolism of the injected cells, in order to
improve the quality of the bioengineered tissues. The non-invasive tracking of long-term
viability and functionality of implanted cells is critical–finding a tool to monitor cell fate
would be a major breakthrough. Finally, alternative approaches (e.g., regenerative pharma-
cology) need to be further developed as stand-alone or combined treatment strategies for
patients with SUI. Overall, there is a huge potential for stem cell therapies in combination
with regenerative pharmacology for the treatment of patients with SUI in the near future.
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D2R dopamine 2 receptors
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DTI diffusion tensor imaging
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FDA Food and Drug Administration
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ICIQ International Consultation on Incontinence Questionnaire
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ICS International Continence Society
ISD intrinsic sphincter deficiency
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MDSC muscle-derived stem cell
MPC muscle progenitor cell
MRI magnetic resonance imaging
MSC mesenchymal stromal cell
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NMES neuromuscular electromagnetic stimulation
pADSC porcine adipose tissue-derived stromal cell
PET positron emission tomography
PRO patient reported outcome
QoL quality of life
SPIO superparamagnetic iron oxide
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SUI stress urinary incontinence
TE tissue engineering
TVT tension free vaginal tape
UI urinary incontinence
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